Research On The Pricing And Equilibrium Strategy Of The Pharmaceutical Supply Chain From The Perspective Of Different Fairness Concerns

With the rapid development of China's economy,the pharmaceutical industry has undergone earth-shaking changes.Drugs are an important commodity related to the safety of human life.The government has long imposed government pricing on drug prices.The prices of drugs have been artificially high for various reasons.With the full implementation of the new medical reform policy,the government has cancelled the pricing of some drugs.The decision marks the official entry of the drug into a market-oriented competitive environment.To achieve marketization of drug prices and establish a reasonable and fair price order is not only to regulate the competition mechanism of the drug market,but also to improve the real problem of high drug prices and expensive medical treatment for the general public.In the actual operation process,enterprises in the pharmaceutical supply chain not only pay attention to maximizing their own interests,but also often show the fair utility concerns caused by the other party's profits or contributions.This article is the operation of the pharmaceutical supply chain from different perspectives of fairness.The strategy of equilibrium analysis has certain theoretical and practical significance.Through literature review,analyze the research status of China's pharmaceutical supply chain,establish a basic drug supply chain game model for medical insurance drugs,apply different concerns(absolute fairness and relative fairness)to the pharmaceutical supply chain,and study a pharmaceutical manufacturing enterprise(leader)And a drug dealer(follower)constitutes a two-tier supply chain system pricing and balancing strategy;then analyzes non-medical drugs,and applies different concerns(absolute fairness and relative fairness)to the drug supply chain,Study a balanced strategy for a competitive two-tier supply chain system consisting of a pharmaceutical manufacturing company(leader)and two drug distributors(followers).The research shows that the fairness behaviors of drug dealers under different fairness models affect the decision-making behavior and system performance of drug supply chain members to varying degrees.The fair concern behavior is a means for manufacturers and distributors to redistribute profits in the drug supply chain.The competitive intensity of drug dealers also affects the pricing decisions of members of the pharmaceutical supply chain to varying degrees.The conclusion of the study explains the reasons for the government to impose the maximum price limit for medical insurance drugs,reasonably arrange the price limit,and prevent the price of medical insurance drugs from being too high.After the price limit is cancelled,the government should determine the reasonable proportion of medical payment,so as to exert its price for the drug market.Guiding role.